Hyperbilirubinemia, a condition characterized by an excess of bilirubin in the blood, is often associated with yellowing of the skin and eyes, a condition known as jaundice. Two distinct types of inherited hyperbilirubinemia are Gilbert's syndrome and Crigler-Najjar syndrome.
Gilbert's syndrome is relatively benign and affects 3-12% of the population. People with this syndrome have a reduced ability to process bilirubin due to a deficiency in the enzyme glucuronyltransferase. Symptoms are typically mild and include intermittent jaundice, often brought on by stress, fasting, or illness.
On the other hand, Crigler-Najjar syndrome is far rarer and more severe, affecting about one in a million individuals. This condition results from a complete or near-complete deficiency of glucuronyltransferase. Individuals with Crigler-Najjar syndrome develop severe jaundice shortly after birth, which can lead to bilirubin encephalopathy or kernicterus, a form of permanent brain damage.
Management of Gilbert's syndrome usually involves simple lifestyle modifications to reduce symptoms. Avoiding triggers such as fasting or dehydration can help prevent episodes of jaundice. It's also important for those with Gilbert's syndrome to inform their healthcare providers about their condition, as certain drugs can affect bilirubin levels.
In contrast, management of Crigler-Najjar syndrome is more involved and typically includes daily phototherapy to help eliminate bilirubin from the body. For those with the more severe type I Crigler-Najjar syndrome, liver transplantation may eventually be necessary.
Prevention measures for these conditions are currently limited, as both are inherited disorders. Genetic counseling can provide valuable information to families with a history of these conditions, offering insight into the risk of recurrence in future children.
Understanding hyperbilirubinemia and its related syndromes can be challenging. Nevertheless, being informed and taking appropriate management steps can significantly enhance quality of life, even with these conditions.
- Watchko, J. F., & Tiribelli, C. (2013). Bilirubin-induced neurologic damage—Mechanisms and management approaches. The New England journal of medicine, 369(21), 2021-2030.
- Bosma, P. J. (2003). Inherited disorders of bilirubin metabolism. Journal of Hepatology, 38(1), 107-117.
- Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., & Chowdhury, N. R. (2000). Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Human mutation, 16(4), 297-306.
- Shapiro, S. M. (2003). Bilirubin toxicity in the developing nervous system. Pediatric Neurology, 29(5), 410-421.
- Gilbert's Syndrome. (2019). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases.
- Knudsen, T. B., & Ebbesen, F. (2000). Infants with Crigler-Najjar syndrome types I and II: treatment with phototherapy and plasmapheresis. Journal of perinatology, 20(7), 450-453.
- Karam, P. E., Maatouk, H., Chehal, A., & Waked, A. (2002). Liver transplantation for Crigler-Najjar syndrome type I: a single center experience. Transplantation, 74(5), 660-663.